Long-term effect of β-blocker in ST-segment elevation myocardial infarction in patients with preserved left...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Current guidelines recommend beta-blockers for acute myocardial infarction (AMI) patients with reduced left ventricular (LV) systolic function.
• The long-term efficacy of beta-blockers in AMI patients with preserved LV systolic function remains uncertain.
• Preserved LV systolic function is defined as an ejection fraction (EF) greater than 40%.

Purpose of the Study:

• To assess the long-term effect of beta-blocker therapy in patients with AMI and preserved LV systolic function who underwent percutaneous coronary intervention (PCI).
• To determine if beta-blockers reduce adverse cardiac events in this specific patient population.

Main Methods:

• Retrospective analysis of 424 AMI patients with preserved LV systolic function (EF > 40%) who underwent PCI between 1997 and 2011.
• Patients were initially divided into beta-blocker (n=197) and no-beta-blocker (n=227) groups.
• Propensity score matching was used to balance baseline characteristics between the groups, resulting in 103 matched pairs (N=206).

Main Results:

• After propensity score matching, beta-blocker therapy was associated with a significant reduction in cardiac death (Hazard Ratio [HR] 0.40, p = 0.04).
• Beta-blocker therapy was not significantly associated with a reduction in major adverse cardiac events (MACE) or all-cause death.
• The median follow-up period was 4.7 years.

Conclusions:

• Beta-blocker therapy is an effective treatment for reducing cardiac death in patients with acute myocardial infarction who underwent PCI and have preserved left ventricular systolic function.
• Further research may be warranted to explore the impact on MACE and all-cause mortality in this cohort.